Article Summary

Molecular tumor testing, targeted therapies, immunotherapy, and new clinical trials are helping stage IV lung cancer patients live longer with better disease control.

Stage IV lung cancer was once considered a death sentence, but advanced treatments are now offering many patients a far better prognosis with improved outcomes and longer life expectancies.

A growing number of clinical trials are offering targeted therapies and new drug treatment options that are working to provide better control of late-stage lung cancers, said Endeavor Health oncologist Carolina Soto Chervin, MD, PhD.

This is particularly important as 45-48% of newly diagnosed non-small cell lung cancer patients are diagnosed with stage IV cancers. “Unfortunately, it’s not uncommon to get diagnosed at this advanced stage,” said Dr. Soto Chervin.

Molecular testing guides personalized lung cancer treatment

Targeted therapies, in particular, are providing more personalized treatment designed to fight specific markers in individual tumors. The advent of next-generation sequencing (NGS) and sophisticated testing of individual tumors has proven enormously beneficial in determining which medications may work best for patients based on their tumor makeup.

Molecular tumor analysis is now one of the first steps in selecting treatment for advanced and metastatic cancers, explained Dr. Soto Chervin. If a tumor doesn’t show a match to one of the growing numbers of targeted therapies, other treatment options may include single agent immunotherapy or a combination of immunotherapy with chemotherapy.

Current studies are also looking at targeted therapies given as stand-alone treatments versus combined with immunotherapies or with the more traditional course of chemotherapy.

Clinical trials are expanding stage IV lung cancer options

Biopharma and other collaborative trials will continue to bring new treatment options for patients with stage III and IV lung cancer. “We currently have multiple clinical trials available for metastatic lung cancer patients,” said Dr. Soto Chervin.

One clinical trial is looking at bi-specific antibodies, newer classes of drugs that use a two-pronged approach going after two different targets in tumors at once, said Dr. Soto Chervin. “It’s too early to have results on this approach, but other studies have shown some efficacy with these medications in other tumor types,” she added. “We’re hopeful this may offer more significant control of the disease.”

The availability of innovative trials at Endeavor Health, combined with a multidisciplinary approach where physicians work collaboratively to make sure each patient receives the best personalized treatment plan, is providing more hope for those with late-stage cancers.

Low-dose CT screening is vital for early lung cancer detection

Dr. Soto Chervin and colleagues continue to encourage smokers, former smokers and others at high risk of developing lung cancer to get screened with a low-dose CT scan.

With low-dose CT scans, doctors can now detect problems long before symptoms appear. When lung cancer is caught early, it becomes far more treatable.

World-class, expert care for lung cancer

If you or a loved one is diagnosed with lung cancer, you’ll find expert, comprehensive care close to home at Endeavor Health Cancer Institute.